News
-
-
PRESS RELEASE
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
Jaguar Health's crofelemer undergoing clinical studies for rare diseases SBS-IF and MVID in multiple regions; Orphan Drug Designation granted by FDA and EMA -
-
PRESS RELEASE
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine
Jaguar Health announces Canalevia-CA1, a canine-specific crofelemer drug for chemotherapy-induced diarrhea in dogs with FDA approval, detailed safety information provided -
-
PRESS RELEASE
Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health Inc. announces extension of conditional approval by FDA for Canalevia®-CA1 drug for chemotherapy-induced diarrhea in dogs and seeks partners for NP300 prescription drug for general diarrhea in dogs at Pet Connect conference -
-
PRESS RELEASE
Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference
Jaguar Health, Inc. to present at NobleCon20 and Emerging Growth Conference. Lisa Conte to present on December 3 and virtually on December 5, 2024. Jaguar focuses on gastrointestinal distress medicines -
-
PRESS RELEASE
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health, Inc. announces extension of FDA approval for Canalevia®-CA1 for chemotherapy-induced diarrhea in dogs, seeks partner for NP300 development at Pet Connect conference
